文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

心脏手术前后无创通气预防心肺并发症:一项临床随机试验

Impact of Noninvasive Ventilation Before and After Cardiac Surgery for Preventing Cardiac and Pulmonary Complications: A Clinical Randomized Trial.
PubMed 文献 · Chest · 2025-02-19
一句话结论高危心脏手术患者术前5天及术后5天加用无创通气,可降低术后1个月心肺衰竭复合终点发生率(55.1% vs 79.8%,RR 0.69)。

这项前瞻性、随机、单中心试验纳入216例被判定为术后心肺衰竭高危的成人心脏手术患者,比较术前5天及术后5天无创通气(NIV)加常规治疗与单纯常规治疗。术后1个月随访期间,NIV组107例中59例(55.1%)发生预设并裁定的心肺衰竭复合终点,无NIV组109例中87例(79.8%)发生(相对风险0.69;95%CI 0.57-0.84;P<.001),获益持续至3个月。两组在插管需求和心内外科ICU及病房住院时间方面无差异。作者认为,心脏手术前后使用NIV可降低高危心脏手术后的心肺衰竭发生率。

要点

  • 高危心脏手术患者术前5天及术后5天加用NIV,术后1个月心肺衰竭复合终点55.1%(59/107) vs 79.8%(87/109),RR 0.69(95%CI 0.57-0.84;P<.001)。
  • NIV获益持续至术后3个月。
  • 两组在插管需求和心内外科ICU及病房住院时间上无差异。
  • 适用人群为被判定为术后心脏或肺衰竭高危的成人心脏手术患者。

适用人群与场景

  • 被判定为术后心脏或肺衰竭高危的成人心脏手术患者。

处置流程与药物剂量

  • NIV组在常规治疗基础上,术前5天及术后5天接受无创通气。

研究设计与关键结果

  • 研究设计:前瞻性、随机、单中心试验,比较心脏手术围术期NIV与标准治疗。
  • 样本量:共纳入216例患者,NIV组107例,无NIV组109例。
  • 主要终点:术后1个月预设并裁定的心肺衰竭复合终点,NIV组59/107(55.1%) vs 无NIV组87/109(79.8%),相对风险0.69(95%CI 0.57-0.84;P<.001)。
  • 关键次要终点:获益持续至3个月;两组插管需求和心内外科ICU及病房住院时间无差异。

证据类型、等级与局限

  • 证据类型:前瞻性、随机、单中心临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于被判定为术后心脏或肺衰竭高危的成人心脏手术患者,作者认为心脏手术前后使用NIV可降低术后心肺衰竭发生率。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov;NCT02302300。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The immediate postoperative period after heart surgery poses a substantial risk of life-threatening complications, notably acute pulmonary and cardiac failure. Use of noninvasive ventilation (NIV) may reduce the incidence of pulmonary or heart failure, or both.

RESEARCH QUESTION: Is the use of NIV before and after cardiac surgery associated with a lower rate of acute pulmonary and heart failure in patients at risk of postoperative complications?

STUDY DESIGN AND METHODS: We designed a prospective, randomized, monocentric trial comparing preoperative and postoperative NIV in cardiac surgery with standard care. Adult patients classified as being at risk of postoperative cardiac or pulmonary failure were allocated to receive NIV for 5 days before and 5 days after surgery in addition to usual care vs usual care alone. The primary outcome was the composite of predefined and adjudicated cardiorespiratory failure at 1 month after cardiac surgery.

RESULTS: Two hundred sixteen patients were included. During the 1-month follow-up period after surgery, the composite outcome occurred in 59 of 107 patients (55.1%) in the NIV group and in 87 of 109 patients (79.8%) in the no NIV group (relative risk, 0.69; 95% CI, 0.57-0.84; P < .001). The benefit persisted at 3 months. No difference between the 2 groups was found in terms of intubation need and length of hospital stay in cardiac and pulmonary surgery ICUs and in cardiac and pulmonary surgery units.

INTERPRETATION: Our results indicate that the use of NIV before and after cardiac surgery reduces the rate of cardiopulmonary failure after high-risk cardiac surgery.

CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02302300; URL: www.

CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Goret M, Pluchon K, Le Mao R, et al. Impact of Noninvasive Ventilation Before and After Cardiac Surgery for Preventing Cardiac and Pulmonary Complications: A Clinical Randomized Trial. Chest. 2025. PMID: 39984118. doi:10.1016/j.chest.2025.02.010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。